SB 203580 is a specific
inhibitor of p38α and p38β which suppresses downstream activation of
MAPKAP kinase-2 and
heat shock protein 27. At low concentrations, it does not inhibit
JNK
c-Jun N-terminal kinases (JNKs), were originally identified as kinases that bind and phosphorylate c-Jun on Ser-63 and Ser-73 within its transcriptional activation domain. They belong to the mitogen-activated protein kinase family, and ar ...
activity. SB-203580 was recently assigned the INN Adezamapimod, and is currently in phase 2 clinical trials to prevent post-operative tissue adhesion.
References
{{organic-compound-stub
4-Pyridyl compounds
Imidazoles
Sulfoxides
Fluoroarenes